RUBY News and Press, Rubius Therapeutics Inc. From 02/07/23

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Kiora Pharmaceuticals (NASDAQ: KPRX ) stock is heading higher on Tuesday thanks to an update on its KIO-101 eye drops. The big news here is the treatment getting investigational new drug app...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: arfa adam / Shutterstock.com Rubius Therapeutics (NASDAQ: RUBY ) stock is falling hard on Tuesday after the biotechnology company received a Nasdaq delisting notice . According to a filing with the U.S. S...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. They increased NVIDIA, Shopify, NIO Inc., SEA Ltd., Roblox, DoorDash, and Ginkgo Bioworks while reducing Illumina, Ferrari N.V., Arthur J. Gallagher & Co., Albemarle, Meta Platform...

Rubius Therapeutics ( NASDAQ: RUBY ) stock fell 5.9% after hours on Wednesday as the firm initiated a review of strategic alternatives to maximize shareholder value, including a sale of all or part of the company or a merger. The firm is also reducing its workforc...

Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an ent...

3 Penny Stocks to Add to Your Watchlist This Week Are penny stocks worth it right now? That’s a tough question to answer, as there are pros and cons to consider. On the one hand, penny stocks are often seen as a high-risk investment, so there’s definitely potential for...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock We’re breaking down the biggest pre-market stock movers for Friday that traders need to know about! We’ve got reverse stock splits, a collaboration, expansion plans, and more to co...

CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced...

Rubius Therapeutics ( NASDAQ: RUBY ) said it was discontinuing ongoing trials of RTX-240 and RTX-224 for advanced solid tumors and was reducing its workforce by 75%. Rubius is restructuring its business and implementing a series of cost-saving measures, which e...

Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023 Discontinuing Ongoing Phase 1 Clinical Trials of RTX-240 and RTX-224 in Advanced Solid ...